|
FR3097123A1
|
|
Combination of markers to predict response to Vx-001
|
|
EP3400954A1
|
|
Vaccine targeting a cryptic tert epitope, for treating lung cancer in a hla-a*0201-positive never-smoker or light-former smoker patient
|
|
EP3400959A1
|
|
Use of a vaccine targeting a cryptic tert epitope, for treating cancer in a hla-a*0201-positive patient having a non-immunogenic tumor expressing tert
|
|
JP2015163067A
|
|
Identification, optimization and use for immunotherapy of shared hla-b*0702 epitopes
|
|
EP2977059A1
|
|
Immunogenic polypeptide composed of HLA-B7 restricted tumor antigen-derived optimized cryptic peptides, and uses thereof
|
|
EP2886127A1
|
|
Method for emulsifying a triepitope peptide with montanide and kits for performing the same
|
|
CA2764760A1
|
|
Identification, optimization and use of shared hla-b*0702 epitopes for immunotherapy
|
|
WO2010112962A1
|
|
Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy
|
|
WO2008010010A1
|
|
Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
|
|
CN101171032A
|
|
Use of native peptides and their optimized derivatives for vaccination
|
|
CA2634480A1
|
|
Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof
|
